

# Press Release

## ProStrakan Group plc

### Board Change

**Galashiels, Scotland, 10 May 2006** - ProStrakan Group plc (LSE: PSK), the European specialty pharmaceutical company, today announces that Michael Bennett, a non-executive director of the Company, is to stand down from the Board of the Company with effect from the conclusion of the Company's AGM to be held later today. As an Investment Director of London Merchant Securities plc ("LMS"), which has been a major investor in ProStrakan for many years and currently holds a 9% shareholding in the Company, Michael Bennett has been a non-executive director of ProStrakan since 2000. His decision to stand down from the Board follows the announcement that Mr. Bennett will be leaving LMS in the medium term to pursue his independent business interests.

**Commenting, Harry Stratford, Chairman of ProStrakan, said: "On behalf of the Board I would like thank Michael for his valuable contribution to ProStrakan and thank him for the insight and advice that he has brought to our discussions during his time as a non-executive director of the Company."**

**ENDS**

**For more information, please contact:**

**ProStrakan** + 44 (0)1896 664000  
Wilson Totten, CEO  
Adrian Gardner, CFO

**Financial Dynamics** + 44 (0)20 7831 3113  
David Yates/ Sarah MacLeod

## **Notes to Editors**

### **ProStrakan**

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the research, development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. The company's therapeutic focus is on bone diseases, women's health and issues relating to the ageing male. Headquartered in Scotland, the company's R&D facilities are situated in Romainville, near Paris, and in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries based in the UK, France, Germany and Spain.

ProStrakan was listed on the London Stock Exchange in June 2005.

On 23 March 2006, the company announced its Preliminary Results for 2005: revenues up 47% to £31.6 million; gross profit up 69% to £16.7 million.

On the same day, the company made two further announcements: firstly, the in-licensing of the UK rights to Tabphyn™, a treatment for benign prostatic hyperplasia, and, secondly, the successful conclusion to the Rectogesic™ MRP (see above).

[www.prostrakan.com](http://www.prostrakan.com)